Publication: Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey
No Thumbnail Available
Date
2022-08-01
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: The efficacy and safety of trifluridine/tipiracil (FTD/TPI) for third-line treatment of metastatic colorectal cancer have been demonstrated. The authors present the Turkish post hoc analysis of the PRECONNECT study. Methods: An international, multicenter, single-arm, open-label, phase IIIb trial evaluating FTD/TPI in patients with >= 2 previous lines of chemotherapy for metastatic colorectal cancer was conducted. The primary end point was safety. Results: In this Turkish cohort (n = 100; eight centers), the most frequent treatment-emergent adverse event was neutropenia (48%). Median progression-free survival was 3.0 months; disease control rate was 36%; quality of life remained stable. Conclusion: Outcomes with FTD/TPI in Turkey are consistent with previous studies and confirm the efficacy and safety of FTD/TPI treatment in the third-line setting.
Description
Keywords
Tıp, Dahili Tıp Bilimleri, İç Hastalıkları, Onkoloji, Sağlık Bilimleri, Medicine, Internal Medicine Sciences, Internal Diseases, Oncology, Health Sciences, ONKOLOJİ, Klinik Tıp, Klinik Tıp (MED), ONCOLOGY, CLINICAL MEDICINE, Clinical Medicine (MED)
Citation
ÖZET A., DANE F., Aykan N. F. , YALÇIN Ş., EVRENSEL T., ÖZKAN M., Karabulut B., Ormeci M. N. , Atasev O., Vidot L., et al., "Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey", FUTURE ONCOLOGY, 2022